The purpose of this prospective multi-center, observational registry in China is to collect clinical baseline, procedural, and follow-up data of all patients treated with TAVR in China and to evaluate short-, mid-, and long-term clinical outcome data of all post-marketing transcatheter valves. Each center will collect baseline and procedural data as well as clinical outcomes for up to 10 years.
Patients with aortic valve disease are evaluated by the cardiac team and indicate TAVR therapy
Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form
Patients with aortic valve disease who have been evaluated by a cardiac team as unsuitable for TAVR
Patients who cannot tolerate the materials or medications associated with this study
Women who are pregnant or breastfeeding
Patients who participated in a clinical trial of another drug or medical device before enrollment